Results 191 to 200 of about 18,044 (238)

Toward Regulatory Convergence and Streamlined Biosimilar Development: Recommendations from an International Qualitative Study. [PDF]

BioDrugs
Car E, Barbier L, Schwarzenberger I, Huys I, Simoens S, Vulto AG.   +5 more
europepmc   +1 more source

Barriers to Biosimilar Approval: Creating Clarity Through the Publication of Product-Class Specific Guidances [PDF]

, 2016
McEnrue, Martin
core  

AVT04, a Biosimilar to Reference Product Ustekinumab, for the Treatment of Plaque Psoriasis: Insights from a Real-World Experience up to 28 Weeks. [PDF]

Dermatol Ther (Heidelb)
Mortato E, Talamonti M, Savastano L, Marcelli L, Tofani L, Gneo V, Marrapodi D, Ingrosso MR, Bianchi L, Galluzzo M.   +9 more
europepmc   +1 more source

Economic evaluation of three domestic bevacizumab biosimilars and the original bevacizumab for treating nonsquamous non-small cell lung cancer in china: a cost-effectiveness analysis. [PDF]

Cost Eff Resour Alloc
Zhang Y, Zhou T, Wu N, Bai Z, Wei J, Cai N, Xu S.   +6 more
europepmc   +1 more source

Biologic Drug Prices in Medicare Part B After Entry of Biosimilars to the Market.

JAMA Netw Open
Abdelaziz A, Winn AN, Dusetzina SB, Mitchell AP.   +3 more
europepmc   +1 more source

The unintended consequences of the inflation reduction act on biosimilar market incentives and Medicare savings. [PDF]

Health Aff Sch
Beinfeld MT, Ghule P, LaMountain F, Wong W, Ko S, Chambers JD.   +5 more
europepmc   +1 more source

Formulation of Recombinant Therapeutic Proteins: Technological Innovation, Regulations, and Evolution Towards Buffer-Free Formulations. [PDF]

Pharmaceutics
Bas TG.
europepmc   +1 more source

NMR-based structural integrity analysis of therapeutic monoclonal antibodies: a comparative study of Humira and its biosimilars. [PDF]

MAbs
Baldisseri D, Luo S, Ancajas CAF, Ortega-Rodriguez U, Fischer C, Zou G, Gu J, Keire D, Piotto M, Zhang B.   +9 more
europepmc   +1 more source

Temporal Trends in the Prescription of Biosimilars and the Status of Switching from Original Biologics to Biosimilars at Individual and Institutional Levels in Japan. [PDF]

Ther Innov Regul Sci
Matsumoto M, Kumazawa R, Ishii-Watabe A, Horiguchi I, Mamiya H, Shibata H, Saito Y, Adomi M, Taniguchi Y, Komiyama J, Sakai R, Iwagami M.   +11 more
europepmc   +1 more source

Antitrust and the Biopharmaceutical Industry: Lessons from Hatch-Waxman and an Early Evaluation of the Biologics Price Competition and Innovation Act of 2009 [PDF]

, 2010
Seamon, Matthew J
core   +1 more source